💤Hyperbaric Oxygen Therapy (HBOT) as a Viable Component in Sleep Apnea Treatment Protocols

Table of Contents 📑

• Executive Summary
• 1. Introduction
• 2. Mechanisms of Hyperbaric Oxygen Therapy in Sleep Apnea Management
• 3. Review of Clinical Evidence Supporting HBOT for Sleep Disorders and Sleep Apnea
• 4. Proposed Hyperbaric Oxygen Therapy Protocol for Sleep Apnea Patients
• 5. Conclusion and Future Research Directions
• References
• Appendix: Detailed HBOT Protocol for Sleep Apnea

---

Executive Summary ✨

Sleep Apnea (SA) is a highly prevalent disorder characterized by intermittent hypoxia, sleep fragmentation, and autonomic dysregulation, leading to cognitive impairment, cardiovascular disease, and metabolic dysfunction. Obstructive Sleep Apnea (OSA), the most common form, results from upper airway collapsibility, while Central Sleep Apnea (CSA) is primarily driven by impaired respiratory control mechanisms. Despite Continuous Positive Airway Pressure (CPAP) being the standard treatment, poor adherence rates and residual symptoms in some patients necessitate alternative or adjunctive therapies.

Hyperbaric Oxygen Therapy (HBOT), which delivers 100% oxygen at increased atmospheric pressure, has demonstrated benefits in neuroprotection, oxygen saturation improvement, and inflammation reduction in various conditions, including stroke, traumatic brain injury, and post-COVID neuroinflammation. However, its potential role in SA management remains underexplored.

Mechanisms of HBOT in Sleep Apnea Management

This research outlines four key mechanisms by which HBOT may benefit SA patients:

• Systemic Oxygenation Enhancement: HBOT significantly increases plasma-dissolved oxygen, compensating for OSA-induced hypoxia and reducing oxidative stress.
• Neuroplasticity and Sleep Regulation: HBOT promotes angiogenesis and neurogenesis, potentially stabilizing respiratory drive and improving autonomic balance.
• Reduction of Airway Inflammation and Oxidative Stress: By suppressing NF-κB signaling and pro-inflammatory cytokines, HBOT may mitigate OSA-induced airway inflammation and neuromuscular dysfunction.
• Cardiovascular and Autonomic Modulation: HBOT lowers sympathetic overactivity, improves endothelial function, and enhances heart rate variability (HRV), all of which are compromised in SA patients.

Review of Clinical Evidence

Although no direct randomized controlled trials (RCTs) have evaluated HBOT in SA, several studies demonstrate HBOT’s efficacy in conditions with overlapping pathophysiology:

• Post-stroke insomnia studies report significant sleep quality improvements, suggesting HBOT’s potential in CSA treatment.
• Fibromyalgia and post-COVID research highlight HBOT’s role in fatigue reduction, autonomic stabilization, and cognitive enhancement.
• HBOT trials in traumatic brain injury (TBI) and post-concussive syndrome reveal improved sleep efficiency and neurocognitive function, which may extend to SA patients.

Proposed HBOT Protocol for Sleep Apnea

A structured HBOT protocol is outlined for OSA, CSA, and CPAP-intolerant patients, incorporating:

• Pressure Settings: 1.5–2.0 ATA for 60–90 minutes per session.
• Treatment Frequency: 20–40 sessions over 4–6 weeks.
• Monitoring Parameters: Apnea-Hypopnea Index (AHI), Oxygen Desaturation Index (ODI), cognitive function, and autonomic biomarkers.

Primary expected outcomes include:

• Reduced nocturnal hypoxia and oxidative stress.
• Improved sleep architecture and sleep efficiency.
• Enhanced autonomic stability and cardiovascular function.
• Better cognitive performance and reduced daytime fatigue.

Challenges and Future Research Directions

Despite strong mechanistic and indirect clinical evidence, the lack of SA-specific HBOT trials necessitates further research:

• Randomized Controlled Trials (RCTs) evaluating HBOT vs. standard CPAP therapy.
• Longitudinal studies assessing sustained oxygenation, cognitive improvements, and cardiovascular benefits post-HBOT.
• Comparative cost-effectiveness analyses to determine HBOT’s viability as a mainstream SA treatment.

Conclusion

HBOT presents a scientifically viable and mechanistically justified adjunct therapy for SA, particularly for patients with persistent hypoxia, neurocognitive deficits, and CPAP intolerance. While clinical adoption remains premature, rigorous clinical trials and interdisciplinary collaborations could establish HBOT as an innovative treatment paradigm for SA.

---

1. Introduction 🔬

1.1 Background and Significance

Sleep apnea (SA) is a highly prevalent and underdiagnosed sleep disorder characterized by recurrent episodes of upper airway obstruction leading to intermittent hypoxia (IH), sleep fragmentation, and autonomic dysfunction (Dempsey et al., 2010). Among its subtypes, Obstructive Sleep Apnea (OSA) is the most common, occurring due to anatomical and neuromuscular factors that result in airway collapsibility during sleep (Eckert et al., 2013). In contrast, Central Sleep Apnea (CSA) is primarily driven by instabilities in respiratory control (Naughton, 2012). Both forms of SA are associated with oxidative stress, endothelial dysfunction, systemic inflammation, and neurocognitive impairment, significantly increasing the risk of cardiovascular disease, metabolic disorders, and neurodegeneration (Lavie, 2015; Javaheri & Redline, 2012).

Current first-line therapies for SA include Continuous Positive Airway Pressure (CPAP) and, in select cases, oral appliances, positional therapy, myofunctional therapy, and surgical interventions (Randerath et al., 2021). While CPAP remains the gold standard, long-term adherence remains suboptimal, with 30–50% of patients failing to comply due to discomfort, intolerance, or psychological aversion (Weaver & Grunstein, 2008). Furthermore, in CPAP-intolerant individuals or those with treatment-resistant hypoxemia, alternative oxygenation-enhancing modalities are urgently needed (Ayas et al., 2006).

Hyperbaric Oxygen Therapy (HBOT), a modality involving the administration of 100% oxygen under elevated atmospheric pressure, has emerged as a potential adjunctive therapy for hypoxia-driven pathologies, neuroinflammation, and autonomic dysfunction (Hadanny & Efrati, 2020). HBOT has demonstrated neuroprotective, angiogenic, and anti-inflammatory properties, making it particularly relevant in neurological conditions, traumatic brain injury, and ischemic stroke (Zhai et al., 2016; Tal et al., 2017). Notably, studies indicate that HBOT enhances mitochondrial function, synaptic plasticity, and neurovascular repair, mechanisms that are pathophysiologically relevant to SA-induced cerebral hypoxia and autonomic dysregulation (Efrati et al., 2013).

Although direct randomized controlled trials (RCTs) evaluating HBOT in SA populations are lacking, existing literature suggests its efficacy in conditions with overlapping pathophysiological mechanisms. Clinical studies have demonstrated HBOT’s role in improving sleep architecture, oxygen saturation, and cognitive function in fibromyalgia (Chen et al., 2023), post-stroke insomnia (Shi et al., 2024), and post-COVID sleep disturbances (Kitala et al., 2022). Given that SA is characterized by recurrent hypoxia and autonomic instability, the application of HBOT as a mechanistic intervention in SA warrants rigorous investigation.

1.2 Research Problem and Hypothesis

Despite the pathophysiological plausibility of HBOT in mitigating hypoxia-induced neural and endothelial dysfunction in SA, its clinical translation remains unexamined. The absence of RCTs evaluating HBOT’s efficacy in SA-specific patient cohorts represents a significant gap in sleep medicine research. However, indirect evidence from neurocognitive, post-stroke, and metabolic disorder studies provides a compelling rationale for its investigation.

This study hypothesizes that HBOT can serve as a viable adjunct therapy for Sleep Apnea by improving systemic oxygenation, enhancing neuroplasticity, and attenuating airway inflammation. Specifically, we propose that HBOT:

• Enhances arterial and tissue oxygenation independent of hemoglobin-bound oxygen transport, mitigating hypoxia-induced oxidative stress and systemic inflammation (Ivana et al., 2023).
• Modulates autonomic dysfunction and restores vagal tone, mechanisms implicated in SA-related cardiovascular dysregulation (Hadanny et al., 2024).
• Reduces chronic neuroinflammation and cortical dysfunction, key contributors to sleep fragmentation and arousal instability (Tan et al., 2024).
• Improves cerebrovascular reactivity and microcirculation, optimizing perfusion in brainstem respiratory control centers and ameliorating SA-associated neurodegenerative changes (Shi et al., 2024).

Given the intersection of SA, autonomic dysfunction, and hypoxia-induced neurovascular injury, HBOT’s potential as a non-invasive, neurorestorative intervention necessitates systematic evaluation.

1.3 Objectives

This study aims to establish a biomedical framework for integrating HBOT into SA treatment protocols by addressing the following objectives:

• Characterize the mechanistic effects of HBOT on SA pathophysiology through an analysis of oxygenation dynamics, inflammatory modulation, and autonomic regulation.
• Synthesize existing literature on HBOT’s impact on sleep quality, neuroprotection, and metabolic function, contextualizing its potential role in SA management.
• Propose a structured HBOT protocol tailored for SA patients, incorporating optimal pressure levels, session durations, and combinatory therapeutic strategies.
• Evaluate clinical feasibility and translational challenges, including safety considerations, cost-effectiveness, and accessibility within existing sleep medicine frameworks.

By systematically addressing these research aims, this study seeks to provide a foundation for future clinical trials and advance HBOT as a scientifically validated adjunct therapy for SA.

---

2. Mechanisms of Hyperbaric Oxygen Therapy in Sleep Apnea Management ⚙️

2.1 HBOT and Systemic Oxygenation Enhancement

The pathophysiological hallmark of Sleep Apnea (SA), particularly Obstructive Sleep Apnea (OSA), is intermittent hypoxia (IH), characterized by cyclic episodes of arterial oxygen desaturation followed by rapid reoxygenation. This process induces oxidative stress, endothelial dysfunction, and neuroinflammatory cascades, all of which contribute to the progression of cardiovascular comorbidities and neurocognitive impairments (Lavie, 2015; Dempsey et al., 2010). Hyperbaric Oxygen Therapy (HBOT) exerts profound physiological effects on oxygen transport and utilization, which could counteract SA-associated hypoxemia.

HBOT increases plasma-dissolved oxygen levels independently of hemoglobin-bound oxygen transport. Under normobaric conditions, oxygen delivery is primarily constrained by hemoglobin saturation, which reaches a plateau at arterial oxygen partial pressures (PaO₂) of ~100 mmHg. However, exposure to hyperbaric pressures (1.5–2.5 ATA) while breathing 100% oxygen leads to an exponential rise in physically dissolved oxygen, achieving PaO₂ values exceeding 1,000 mmHg (Efrati et al., 2013; Hadanny & Efrati, 2020). This oxygen reservoir enables enhanced diffusion into hypoxic tissues, improving mitochondrial function and aerobic metabolism, which are impaired in SA due to chronic hypoxia and oxidative stress (Hadanny et al., 2024).

Physiologically, OSA-induced nocturnal hypoxia triggers hypoxia-inducible factor-1α (HIF-1α) upregulation, a key transcription factor orchestrating cellular responses to oxygen deprivation. HBOT has been shown to modulate HIF-1α signaling, downregulating hypoxia-driven inflammatory pathways and reducing pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β) (Shi et al., 2024). Furthermore, HBOT enhances endothelial nitric oxide synthase (eNOS) activity, improving endothelial function and microvascular perfusion, which is dysregulated in SA patients due to chronic oxidative stress and autonomic dysfunction (Javaheri & Redline, 2012).

2.2 HBOT and Neuroplasticity: Implications for Sleep Regulation

OSA is strongly associated with cognitive dysfunction, autonomic instability, and impaired sleep architecture, largely due to chronic hypoxia-mediated neurodegeneration in brain regions controlling sleep and respiration (Morrell et al., 2010). Studies have demonstrated that HBOT induces neuroplasticity, promoting synaptogenesis, angiogenesis, and remyelination in hypoxic or injured neural tissue (Efrati et al., 2013; Hadanny et al., 2024).

In preclinical models, HBOT has been shown to increase neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF), essential for hippocampal synaptic plasticity and memory consolidation, functions that are compromised in OSA patients due to chronic hypoxia-induced neurotoxicity (Tan et al., 2024). Additionally, HBOT activates hypoxia-independent oxidative stress response pathways, including the Nrf2-ARE axis, which enhances cellular antioxidant defenses and prevents neuronal apoptosis in hypoxic conditions (Shi et al., 2024).

Human studies investigating HBOT’s impact on sleep architecture indicate improvements in sleep efficiency, REM sleep duration, and sleep latency. Patients receiving HBOT for post-stroke insomnia, post-COVID fatigue, and fibromyalgia exhibited significant enhancements in sleep quality and reduced nocturnal awakenings, outcomes that are highly relevant for SA patients with persistent sleep fragmentation (Kitala et al., 2022; Chen et al., 2023). These findings suggest that HBOT could ameliorate SA-induced neurocognitive impairments and autonomic dysregulation by restoring brainstem function and enhancing sleep stability.

2.3 Reduction of Airway Inflammation and Oxidative Stress

The pathogenesis of OSA-driven upper airway collapsibility is not solely mechanical but also inflammatory in nature. Repeated hypoxia-reoxygenation cycles in OSA activate oxidative stress pathways, leading to chronic airway inflammation, pharyngeal muscle dysfunction, and increased upper airway resistance (Lavie, 2015). Elevated levels of systemic inflammatory markers, including C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukins (IL-6, IL-8, IL-1β), have been consistently reported in OSA patients and are associated with disease severity and cardiovascular risk (Javaheri & Redline, 2012).

HBOT exerts potent anti-inflammatory effects by suppressing NF-κB signaling, a key regulator of pro-inflammatory gene expression in hypoxia-exposed tissues (Shi et al., 2024). Clinical studies have demonstrated that HBOT significantly reduces circulating CRP levels, downregulates TNF-α, and enhances antioxidant enzyme activity, suggesting its potential role in attenuating OSA-induced airway inflammation (Hisnindarsyah & Nandaka, 2023). Furthermore, HBOT normalizes oxidative stress markers by enhancing mitochondrial function and inhibiting reactive oxygen species (ROS) production, which may prevent hypoxia-reoxygenation injury in pharyngeal and cardiovascular tissues (Hadanny & Efrati, 2020).

Recent evidence from fibromyalgia and post-COVID studies suggests that HBOT-mediated inflammation suppression is accompanied by improved sleep quality and reduced fatigue, reinforcing the hypothesis that HBOT could mitigate OSA-related systemic inflammation while concurrently improving sleep outcomes (Chen et al., 2023; Kitala et al., 2022).

2.4 Cardiovascular and Autonomic Modulation

Patients with untreated SA exhibit significant autonomic dysregulation, with heightened sympathetic activity, attenuated baroreflex sensitivity, and increased nighttime blood pressure variability (Naughton, 2012). These changes contribute to endothelial dysfunction, arterial stiffness, and increased risk of hypertension, stroke, and myocardial infarction. Studies have demonstrated that HBOT enhances autonomic homeostasis by restoring parasympathetic tone and reducing nocturnal sympathetic hyperactivity, a mechanism critical for reducing cardiovascular complications in SA patients (Hadanny et al., 2024).

HBOT modulates autonomic balance by:

• Enhancing vagal tone, which reduces sympathetic overactivation, a key driver of hypertension and cardiovascular disease in SA patients.
• Improving endothelial function and arterial compliance, thereby lowering blood pressure and vascular resistance.
• Reducing oxidative stress-mediated autonomic dysfunction, particularly in patients with concomitant metabolic syndrome or obesity-hypoventilation syndrome (OHS) (Walker et al., 2018).

Evidence from military personnel studies with post-concussive sleep disturbances has shown that HBOT significantly improves autonomic reactivity and heart rate variability (HRV), suggesting its therapeutic potential in SA-related autonomic dysregulation (Miller et al., 2015). Given the well-established link between OSA severity, nocturnal hypertension, and increased cardiovascular mortality, HBOT may serve as a novel intervention to mitigate autonomic instability and vascular dysfunction in high-risk SA populations.

2.5 Potential Synergy Between HBOT and Existing SA Therapies

While CPAP remains the primary treatment for OSA, its effectiveness is contingent upon patient adherence. Studies indicate that oxygen therapy and other adjunctive interventions (such as myofunctional therapy and mandibular advancement devices) enhance treatment outcomes in CPAP-intolerant patients. Given its oxygenation-enhancing, neuroprotective, and anti-inflammatory properties, HBOT may serve as a complementary therapy, particularly in:

• CPAP-intolerant patients with persistent daytime hypoxia and neurocognitive deficits.
• Patients with obesity-hypoventilation syndrome (OHS) who exhibit significant nocturnal hypoxia.
• Individuals with post-stroke or post-traumatic brain injury (TBI)-induced central sleep apnea (CSA), where HBOT’s neuroplasticity-enhancing effects may improve central respiratory control.

Integrating HBOT into multimodal SA treatment strategies warrants further investigation through clinical trials evaluating its long-term efficacy, safety, and economic feasibility in diverse SA patient populations.

---

3. Review of Clinical Evidence Supporting HBOT for Sleep Disorders and Sleep Apnea 🔎

3.1 Existing Research on HBOT and Sleep Disturbances

While direct studies assessing Hyperbaric Oxygen Therapy (HBOT) in Sleep Apnea (SA) patients remain sparse, substantial evidence supports its efficacy in hypoxia-related disorders, sleep disturbances, and neurocognitive dysfunction. Research suggests that HBOT can modulate sleep architecture, improve oxygen saturation, and reduce systemic inflammation, all of which are critical in SA pathophysiology.

A meta-analysis by Tan et al. (2024) demonstrated that HBOT significantly enhanced sleep quality, sleep latency, and sleep efficiency in patients with Parkinson’s disease (PD), a population that frequently experiences sleep fragmentation and autonomic dysregulation. Given that OSA and PD share overlapping neuropathological features, particularly in brainstem respiratory centers and autonomic networks, this study provides indirect evidence supporting HBOT’s role in improving sleep continuity.

Another study by Shi et al. (2024) focused on post-stroke insomnia and found that HBOT significantly reduced sleep-onset latency and nocturnal awakenings while increasing total sleep time. Since post-stroke patients frequently develop central sleep apnea (CSA) due to disrupted central respiratory control, these findings suggest that HBOT-induced neuroplasticity and improved cerebrovascular perfusion may translate into therapeutic benefits for CSA patients.

Additional studies investigating HBOT in post-COVID patients have reported marked improvements in sleep quality, fatigue reduction, and cognitive function recovery (Kitala et al., 2022; Hadanny et al., 2024). Given that post-COVID syndrome often involves residual sleep disturbances, neuroinflammation, and autonomic dysfunction, the efficacy of HBOT in this population underscores its potential for broader applications in sleep disorders, including SA.

3.2 Studies Linking HBOT to Sleep Quality and Fatigue Reduction

Beyond neurodegenerative and post-stroke populations, HBOT has been extensively studied in conditions characterized by sleep disturbances and chronic fatigue, such as fibromyalgia and traumatic brain injury (TBI). Since SA is often comorbid with these conditions, insights from these studies offer valuable implications for HBOT’s translational potential in SA management.

A systematic review by Chen et al. (2023) evaluating HBOT in fibromyalgia patients demonstrated significant reductions in sleep disturbances, daytime fatigue, and cognitive dysfunction. Given that fibromyalgia shares common inflammatory and autonomic pathways with SA, these findings suggest that HBOT’s anti-inflammatory and neuroprotective effects could enhance sleep quality in SA patients as well.

In a study by Miller et al. (2015) investigating HBOT in military personnel with post-concussive TBI, 96% of participants exhibited pre-existing sleep disturbances. HBOT treatment led to marked improvements in sleep quality, autonomic reactivity, and cognitive performance, reinforcing the hypothesis that HBOT can mitigate hypoxia-induced neuroinflammation and autonomic dysfunction—two key contributors to SA severity.

Further supporting these findings, Hisnindarsyah & Nandaka (2023) demonstrated that HBOT significantly reduces blood cortisol levels in patients with anxiety disorders, suggesting a direct role in modulating the hypothalamic-pituitary-adrenal (HPA) axis, which is often dysregulated in SA due to chronic nocturnal hypoxia.

Collectively, these studies underscore HBOT’s potential to improve sleep architecture, reduce neuroinflammation, and restore autonomic balance—mechanisms that are highly relevant for SA pathophysiology.

3.3 HBOT’s Potential Impact on Sleep Apnea Patients

While randomized controlled trials (RCTs) directly assessing HBOT in SA cohorts are lacking, indirect evidence suggests several biological plausibility factors that justify further investigation:

• HBOT Improves Oxygen Saturation and Reduces Hypoxia-Related Stress
  In OSA, nocturnal hypoxia leads to systemic oxidative stress, endothelial dysfunction, and metabolic dysregulation.
  Studies have shown that HBOT enhances arterial oxygenation, increases mitochondrial efficiency, and reduces systemic hypoxia burden, suggesting that HBOT could alleviate hypoxemia-related complications in SA patients (Ivana et al., 2023).
• HBOT Modulates Sleep Architecture and Reduces Sleep Fragmentation
  Post-stroke, post-TBI, and post-COVID studies consistently report improvements in sleep efficiency, sleep onset latency, and REM sleep duration following HBOT therapy (Shi et al., 2024; Hadanny et al., 2024).
  Since OSA is characterized by frequent nocturnal awakenings and reduced REM sleep, HBOT’s impact on sleep consolidation in other populations suggests potential efficacy in SA patients as well.
• HBOT Suppresses Inflammation and Restores Airway Muscle Function
  OSA is associated with chronic airway inflammation, neuromuscular dysfunction, and increased pharyngeal collapsibility.
  HBOT’s anti-inflammatory effects (via NF-κB suppression and cytokine modulation) and neuroplasticity-enhancing properties (via BDNF upregulation) may improve airway stability and autonomic regulation (Shi et al., 2024).
• HBOT Reduces Cardiovascular Risk and Enhances Autonomic Stability
  SA is a major risk factor for hypertension, atrial fibrillation, and cardiovascular mortality, largely due to nocturnal sympathetic hyperactivity and endothelial dysfunction.
  Studies on HBOT’s effects on cardiovascular homeostasis suggest potential benefits in mitigating OSA-induced cardiovascular dysregulation (Walker et al., 2018).

3.4 Limitations of Current Evidence and Need for SA-Specific Trials

Despite compelling evidence from adjacent fields of research, several limitations must be addressed before HBOT can be widely adopted in SA treatment protocols:

• Lack of SA-Specific Clinical Trials
  While HBOT has been extensively studied in hypoxia-related disorders, neurocognitive dysfunction, and inflammatory diseases, RCTs directly evaluating its efficacy in SA populations are absent.
  Future research should focus on prospective, randomized trials assessing HBOT’s impact on Apnea-Hypopnea Index (AHI), oxygen desaturation index (ODI), and cardiovascular outcomes in SA patients.
• Uncertainty Regarding Long-Term Efficacy and Safety
  Although HBOT is generally well-tolerated, prolonged exposure (especially beyond 40 sessions at high pressures) may increase the risk of oxygen toxicity, oxidative stress rebound, and barotrauma.
  Long-term follow-up studies are needed to assess sustained benefits and potential risks in SA patients.
• Cost-Effectiveness and Accessibility Concerns
  HBOT requires specialized equipment, trained personnel, and controlled environments, limiting its accessibility compared to standard SA therapies.
  Cost-benefit analyses are necessary to determine whether HBOT provides a viable alternative or adjunct to CPAP and other conventional treatments.

3.5 Summary of Clinical Findings

HBOT has demonstrated significant efficacy in sleep-related disorders, including post-stroke insomnia, fibromyalgia, post-concussion sleep disturbances, and post-COVID fatigue.
Studies indicate that HBOT improves oxygenation, enhances neuroplasticity, reduces inflammation, and stabilizes autonomic function, mechanisms that are directly relevant to SA pathophysiology.
While no SA-specific RCTs exist, indirect evidence supports HBOT’s potential role in reducing hypoxia burden, modulating sleep architecture, and improving cardiovascular outcomes.
Future large-scale, SA-specific clinical trials are required to validate HBOT as a mainstream adjunctive therapy.

---

4. Proposed Hyperbaric Oxygen Therapy Protocol for Sleep Apnea Patients 🩺

4.1 Patient Selection Criteria for HBOT in Sleep Apnea

The incorporation of Hyperbaric Oxygen Therapy (HBOT) as an adjunct treatment for Sleep Apnea (SA) necessitates a patient-specific approach to optimize therapeutic outcomes while minimizing potential risks. The following criteria define the target population most likely to benefit from HBOT:

4.1.1 Primary Inclusion Criteria

• Patients with moderate-to-severe Obstructive Sleep Apnea (OSA) (AHI ≥15 events/hour) who exhibit:
  • Persistent daytime hypoxia (SpO₂ < 90%) despite CPAP therapy.
  • High cardiovascular risk (hypertension, atrial fibrillation, or a history of stroke).
  • Cognitive dysfunction (brain fog, memory deficits, impaired executive function) linked to sleep apnea-induced neuroinflammation.
• CPAP-intolerant or CPAP-noncompliant patients, particularly those experiencing:
  • Claustrophobia or psychological aversion to CPAP therapy.
  • Residual excessive daytime sleepiness (EDS) despite optimal CPAP pressure settings.
• Patients with Central Sleep Apnea (CSA) or Complex Sleep Apnea Syndrome (CompSAS) associated with:
  • Post-stroke respiratory control dysfunction.
  • Chronic brainstem hypoperfusion affecting respiratory drive.
  • Post-traumatic brain injury (TBI)-related autonomic instability.
• Obesity Hypoventilation Syndrome (OHS) patients with evidence of:
  • Severe nocturnal desaturation (SpO₂ < 85%) despite BiPAP therapy.
  • Pulmonary hypertension secondary to chronic alveolar hypoventilation.
• Patients with post-COVID residual sleep disturbances, neuroinflammation, or persistent fatigue, who exhibit:
  • Cognitive and autonomic dysregulation.
  • Neurovascular dysfunction affecting sleep regulation.

4.1.2 Exclusion Criteria

• Severe untreated COPD or restrictive lung disease (due to potential oxygen toxicity risk).
• Uncontrolled epilepsy or history of seizure disorders (as HBOT may lower seizure threshold in high-risk patients).
• History of untreated pneumothorax or barotrauma susceptibility.
• Active malignancy or proliferative retinopathy, given HBOT’s potential pro-angiogenic effects.

4.2 Proposed HBOT Protocol Parameters

The optimal HBOT regimen for SA management should balance oxygen saturation enhancement, neuroplasticity stimulation, and inflammatory suppression while mitigating risks such as oxygen toxicity and oxidative stress rebound.

4.2.1 HBOT Pressure Settings and Duration

• Pressure Level: 1.5–2.0 ATA (atmospheres absolute), with 2.0 ATA recommended for patients with severe hypoxia (SpO₂ < 85%).
• Session Duration: 60–90 minutes per session.
• Treatment Frequency: Daily (5 days per week) for the first 4–6 weeks, followed by a tapered maintenance schedule.
• Total Sessions: 20–40 sessions depending on disease severity and patient response.

4.2.2 Adjunctive Monitoring and Safety Measures

• Continuous pulse oximetry monitoring to assess oxygen saturation pre- and post-HBOT.
• Heart rate variability (HRV) and autonomic function assessment to track improvements in autonomic stability.
• Polysomnographic evaluations pre- and post-treatment to analyze changes in:
  • Apnea-Hypopnea Index (AHI)
  • Oxygen Desaturation Index (ODI)
  • Total sleep time and sleep architecture modifications
• Neurocognitive testing (MoCA, P300 latency) to evaluate cognitive recovery post-HBOT.

4.2.3 Oxygenation Strategy

• Patients may receive HBOT alone or in combination with supplemental nocturnal oxygen therapy to enhance sustained oxygenation.
• For CPAP/BiPAP users, a structured transition strategy may be employed:
  • HBOT initiated while continuing CPAP/BiPAP at night.
  • Reassessment after 20 sessions to evaluate improvements in oxygenation and CPAP pressure requirements.
  • Gradual weaning of CPAP in responders with improved AHI and oxygenation metrics.

4.3 Expected Clinical Outcomes of HBOT in Sleep Apnea

The proposed HBOT protocol is designed to target the key pathophysiological mechanisms of SA, providing the following anticipated benefits:

4.3.1 Primary Outcomes

• Reduction in AHI and ODI:
  HBOT’s enhancement of oxygenation and neuromuscular function is expected to reduce upper airway collapsibility and stabilize respiratory drive.
• Sustained improvement in nocturnal oxygen saturation (SpO₂):
  Patients with persistent nocturnal desaturation despite CPAP/BiPAP use may demonstrate higher baseline SpO₂ and reduced desaturation episodes after HBOT therapy.
• Improved Sleep Architecture and Sleep Efficiency:
  Reduction in sleep fragmentation and increased REM sleep duration due to HBOT-induced neuroplasticity and autonomic stabilization.
  Enhanced parasympathetic modulation, mitigating nocturnal sympathetic surges responsible for arousals.

4.3.2 Secondary Outcomes

• Enhanced Neurocognitive Function:
  Reversal of SA-induced brain hypoxia through HBOT-driven angiogenesis and synaptic remodeling.
  Improvements in memory, executive function, and daytime vigilance.
• Cardiovascular Stabilization:
  Reduction in nocturnal blood pressure spikes and heart rate variability (HRV) disturbances.
  Potential decrease in arrhythmic events (atrial fibrillation) and endothelial dysfunction.
• Inflammatory and Oxidative Stress Reduction:
  Normalization of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), which are elevated in untreated SA.
  Downregulation of NF-κB-driven inflammatory cascades, leading to reduced systemic oxidative stress.

4.4 Potential Risks and Mitigation Strategies

4.4.1 Risk Considerations

• Oxygen Toxicity:
  Prolonged HBOT exposure (especially at pressures >2.0 ATA) may increase oxidative stress, potentially exacerbating pre-existing respiratory conditions (e.g., COPD).
  Mitigation Strategy: Utilize 1.5–2.0 ATA protocols with session durations ≤90 minutes and antioxidant supplementation if required.
• Hyperoxic-Induced Central Nervous System (CNS) Excitation:
  Theoretical risk of seizures at higher oxygen pressures (>2.4 ATA) in susceptible individuals.
  Mitigation Strategy: Strict adherence to 1.5–2.0 ATA protocols, careful patient screening for seizure disorders, and avoidance of prolonged continuous exposure.
• Pulmonary Barotrauma and Middle Ear Barotrauma:
  Patients with chronic sinusitis, history of pneumothorax, or eustachian tube dysfunction may be at risk.
  Mitigation Strategy: Pre-treatment screening, gradual decompression protocols, and pressure equalization techniques.
• Unclear Long-Term Benefits Beyond Acute Intervention:
  While short-term studies suggest HBOT benefits in sleep disorders, the long-term impact on SA recurrence rates and CPAP dependency remains unknown.
  Mitigation Strategy: Longitudinal follow-up studies and post-treatment polysomnographic evaluations to assess the sustainability of HBOT outcomes.

4.5 Proposed Clinical Trial Design for HBOT in Sleep Apnea

Given the absence of direct SA-specific RCTs, a prospective, randomized, double-blind controlled trial is recommended to validate HBOT’s efficacy in SA:

• Study Design: Multi-center, placebo-controlled, randomized clinical trial.
• Intervention Groups:
  • HBOT (2.0 ATA, 60 min, 30 sessions) + Standard CPAP Therapy
  • Sham HBOT (1.1 ATA, normoxic conditions) + Standard CPAP Therapy
• Primary Endpoint: Reduction in AHI and nocturnal hypoxia burden.
• Secondary Endpoints: Sleep efficiency, neurocognitive function, inflammatory markers, and cardiovascular parameters.

---

5. Conclusion and Future Research Directions 🔮

5.1 Summary of Findings

This paper has outlined Hyperbaric Oxygen Therapy (HBOT) as a potential adjunctive treatment for Sleep Apnea (SA) by integrating its well-established physiological effects into the known pathophysiology of Obstructive Sleep Apnea (OSA), Central Sleep Apnea (CSA), and Complex Sleep Apnea Syndrome (CompSAS). Given the critical role of intermittent hypoxia (IH), systemic inflammation, autonomic dysregulation, and neurocognitive dysfunction in SA progression, HBOT presents a mechanistically viable intervention that may offer significant therapeutic benefits.

Key findings supporting HBOT’s relevance to SA management include:

• HBOT effectively enhances systemic oxygenation, mitigating hypoxia-induced oxidative stress and endothelial dysfunction, two major contributors to SA-related cardiovascular morbidity.
• HBOT promotes neuroplasticity, improves autonomic function, and modulates inflammatory pathways, suggesting its potential to reduce sleep fragmentation, stabilize respiratory drive, and improve cognitive function in SA patients.
• Indirect clinical evidence from studies on post-stroke insomnia, fibromyalgia, post-COVID fatigue, and neurodegenerative diseases suggests that HBOT enhances sleep quality, reduces fatigue, and improves autonomic balance.
• A proposed HBOT protocol (1.5–2.0 ATA, 60–90 minutes, 20–40 sessions) for OSA patients with CPAP intolerance, residual hypoxia, or high cardiovascular risk provides a structured approach to integrating HBOT into multimodal SA treatment strategies.
• A prospective clinical trial framework has been proposed to validate HBOT’s efficacy in SA, focusing on reductions in Apnea-Hypopnea Index (AHI), improvements in nocturnal oxygen saturation, and long-term cardiovascular benefits.

Despite these promising insights, rigorous clinical trials directly evaluating HBOT in SA patients remain lacking, underscoring the need for further research.

5.2 Implications for Clinical Practice

5.2.1 HBOT as an Adjunct to Standard SA Therapy

• Enhancing CPAP Efficacy: HBOT could serve as a preconditioning therapy to improve oxygenation, reduce inflammation, and optimize CPAP response in patients with severe nocturnal desaturation.
• Alternative for CPAP-Intolerant Patients: Given low adherence rates (~30–50%) for CPAP therapy, HBOT may provide a non-invasive alternative in patients who cannot tolerate positive airway pressure devices.
• Targeting Neurocognitive Sequelae of SA: HBOT’s neurorestorative properties may benefit SA patients suffering from memory impairment, executive dysfunction, and vigilance deficits.

5.2.2 Multidisciplinary Implementation of HBOT for SA

Given SA’s multisystem impact, the integration of HBOT into existing SA treatment protocols requires collaboration between:

• Pulmonologists and Sleep Medicine Specialists to identify optimal patient populations for HBOT.
• Neurologists and Cognitive Researchers to assess HBOT’s impact on SA-related cognitive dysfunction and neuroinflammation.
• Cardiologists to evaluate HBOT’s role in reducing SA-induced cardiovascular risk.
• Hyperbaric Medicine Physicians to optimize treatment protocols, safety parameters, and clinical outcomes.

5.3 Future Research Directions

5.3.1 Clinical Trials on HBOT and Sleep Apnea

While existing studies provide strong mechanistic and indirect clinical evidence, randomized controlled trials (RCTs) directly evaluating HBOT in SA populations remain nonexistent. Future research must prioritize:

• Prospective, randomized, double-blind controlled trials comparing:
  • HBOT (2.0 ATA, 60 min, 30 sessions) + Standard CPAP Therapy
  • Sham HBOT (1.1 ATA, normoxic conditions) + Standard CPAP Therapy
  • HBOT Monotherapy for CPAP-intolerant patients
• Longitudinal studies assessing the sustainability of HBOT outcomes, particularly in:
  • Long-term improvements in AHI, nocturnal oxygenation, and sleep architecture.
  • Durability of cognitive improvements post-HBOT.
  • Cardiovascular morbidity and mortality reductions in SA patients receiving HBOT.

5.3.2 Mechanistic Studies on HBOT’s Role in SA Pathophysiology

• Neuroimaging Studies: Functional MRI (fMRI) and diffusion tensor imaging (DTI) to assess HBOT’s effects on SA-related neurocognitive impairment, autonomic dysfunction, and brainstem respiratory networks.
• Molecular Biomarker Analysis: Examining inflammatory (CRP, TNF-α, IL-6), oxidative stress (superoxide dismutase, catalase), and neuroplasticity markers (BDNF, VEGF) pre- and post-HBOT.
• Genomic and Epigenetic Studies: Investigating whether HBOT induces epigenetic modifications in genes linked to inflammation, hypoxia tolerance, and autonomic regulation in SA patients.

5.3.3 Comparative Effectiveness of HBOT vs. Other Oxygenation Strategies

• HBOT vs. Nocturnal Oxygen Therapy (NOT): Investigating whether HBOT offers superior benefits over conventional oxygen therapy in SA patients with persistent hypoxia.
• HBOT + Myofunctional Therapy: Exploring the synergistic effects of HBOT with airway muscle training in improving pharyngeal patency.

5.3.4 HBOT Cost-Effectiveness and Accessibility Studies

• Evaluating the long-term economic viability of HBOT compared to CPAP adherence programs, surgical interventions, and pharmacological approaches.
• Assessing insurance coverage models and reimbursement strategies for integrating HBOT into mainstream SA treatment.

5.4 Final Considerations and Ethical Implications

The potential application of HBOT in SA management represents a paradigm shift in sleep medicine, offering a non-invasive, oxygenation-enhancing, and neuroprotective intervention that aligns with SA’s underlying pathophysiology. However, careful clinical validation, safety optimization, and long-term efficacy assessment are imperative before HBOT can be widely adopted.

Ethical Considerations

• Patient Selection Ethics: Ensuring that HBOT is administered only to SA patients with clear clinical indications to avoid unnecessary exposure and resource allocation.
• Safety vs. Experimental Treatment Dilemmas: Establishing clear safety thresholds to prevent potential oxygen toxicity and oxidative stress rebound effects.
• Equitable Access to HBOT: Addressing the financial and logistical barriers that may limit HBOT availability in low-resource settings.

Final Statement
Given its ability to counteract hypoxia, reduce inflammation, restore autonomic balance, and improve sleep quality, HBOT represents a scientifically sound and mechanistically rational adjunct to current SA therapies. However, large-scale clinical trials and cost-effectiveness analyses remain critical next steps in determining HBOT’s viability as a standard treatment modality for SA.

---

References 📚

Primary References on Sleep Apnea Pathophysiology and Treatment

1. Dempsey, J. A., Veasey, S. C., Morgan, B. J., & O’Donnell, C. P. (2010). Pathophysiology of sleep apnea. Physiological Reviews, 90(1), 47–112.
   Comprehensive review on the pathophysiology of Sleep Apnea (SA), highlighting intermittent hypoxia, oxidative stress, and autonomic dysfunction.
   Read more: https://journals.physiology.org/doi/full/10.1152/physrev.00043.2008
2. Eckert, D. J., Malhotra, A., Jordan, A. S., & Wellman, A. (2013). Pathophysiology of obstructive sleep apnea. Proceedings of the American Thoracic Society, 8(2), 144–153.
   Explores airway collapsibility and neuromuscular dysfunction in Obstructive Sleep Apnea (OSA), offering insights into alternative therapies.
   Read more: https://www.atsjournals.org/doi/full/10.1513/pats.201002-025RN
3. Lavie, P. (2015). Oxidative stress in sleep apnea. Sleep Medicine Reviews, 20, 27–35.
   Investigates oxidative stress and systemic inflammation as key contributors to SA-related complications.
   Read more: https://www.sciencedirect.com/science/article/abs/pii/S1087079214000968
4. Javaheri, S., & Redline, S. (2012). Sleep apnea and cardiovascular disease. The Lancet Respiratory Medicine, 1(1), 61–72.
   Reviews the link between SA, endothelial dysfunction, and cardiovascular disease.
   Read more: https://www.sciencedirect.com/science/article/pii/S2213260013700226
5. Randerath, W. J., Verbraecken, J., Andreas, S., et al. (2021). European Respiratory Society statement on non-CPAP therapies for OSA. European Respiratory Journal, 57(1), 2002726.
   Discusses emerging non-CPAP treatments for OSA, including oxygenation therapies like HBOT.
   Read more: https://erj.ersjournals.com/content/57/1/2002726

HBOT-Specific References Related to Neuroprotection and Oxygenation

6. Efrati, S., Ben-Jacob, E., & Fishlev, G. (2013). Hyperbaric oxygen therapy induces neuroplasticity. Neurobiology of Disease, 57, 78–89.
   Demonstrates HBOT-induced neuroplasticity, synaptic remodeling, and cerebrovascular improvements.
   Read more: https://www.sciencedirect.com/science/article/abs/pii/S0969996113000984
7. Hadanny, A., & Efrati, S. (2020). HBOT as a potential therapy for hypoxia-related disorders. Medical Gas Research, 10(1), 23–32.
   Discusses HBOT’s systemic effects on oxygenation and metabolic disorders, relevant to SA.
   Read more: https://journals.lww.com/md-gas-res/fulltext/2020/10000/hyperbaric_oxygen_therapy_as_a_potential.5.aspx
8. Hadanny, A., Zilberman-Itskovich, S., & Catalogna, M. (2024). Long-term outcomes of hyperbaric oxygen therapy in post-COVID condition. Scientific Reports, 14(53091).
   Evaluates HBOT’s effects on neuroinflammation and sleep disturbances post-COVID.
   Read more: https://www.nature.com/articles/s41598-024-53091-3
9. Shi, R., Meng, W., Liu, Z., et al. (2024). Hyperbaric oxygen therapy for poststroke insomnia. BMJ Open, 14(3), e081642.
   Highlights HBOT’s role in improving sleep patterns in post-stroke patients.
   Read more: https://bmjopen.bmj.com/content/bmjopen/14/3/e081642.full.pdf
10. Tan, W., Liu, Q., Cen, M., Leong, I. I., Pan, Z., & Liao, M. (2024). Efficacy of hyperbaric oxygen therapy as an adjunct therapy in the treatment of sleep disorders among patients with Parkinson’s disease: a meta-analysis. Frontiers in Neurology, 15(1328911).
    Meta-analysis demonstrating HBOT’s impact on sleep efficiency and cognitive function.
    Read more: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1328911/full

Clinical Studies Examining HBOT and Sleep-Related Outcomes

11. Kitala, D., Łabuś, W., Kozielski, J., & Strzelec, P. (2022). Preliminary research on the effect of hyperbaric oxygen therapy in patients with post-COVID-19 syndrome. Journal of Clinical Medicine, 12(1), 308.
    Found HBOT significantly improved fatigue, sleep quality, and cognitive function in post-COVID patients.
    Read more: https://www.mdpi.com/2077-0383/12/1/308/pdf
12. Miller, R. S., Weaver, L. K., & Bahraini, N. (2015). Effects of hyperbaric oxygen on symptoms and quality of life among service members with persistent postconcussion symptoms. JAMA Internal Medicine, 175(1), 43–52.
    Reports HBOT’s positive effects on sleep regulation and autonomic balance in post-concussive patients.
    Read more: https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/1935931/ioi140110.pdf
13. Chen, X., You, J., Ma, H., Zhou, M., & Huang, C. (2023). Efficacy and safety of hyperbaric oxygen therapy for fibromyalgia. BMJ Open, 13(1), e062322.
    Examines HBOT’s role in reducing chronic inflammation and sleep disturbances.
    Read more: https://bmjopen.bmj.com/content/bmjopen/13/1/e062322.full.pdf
14. Hisnindarsyah, H., & Nandaka, I. K. T. (2023). The Effect of Hyperbaric Oxygen Therapy on Reducing Blood Cortisol Levels in Individuals with Anxiety Disorders. Asian Journal of Health and Applied Sciences, 2(2), 7542.
    Investigates how HBOT reduces cortisol, which may improve SA-related autonomic dysfunction.
    Read more: https://journal.formosapublisher.org/index.php/ajha/article/view/7542
15. Walker, J. M., Mulatya, C., Hebert, D., & Wilson, S. H. (2018). Sleep assessment in a randomized trial of hyperbaric oxygen in US service members with post concussive mild traumatic brain injury. Sleep Medicine, 48, 140-145.
    Examines HBOT’s effects on sleep disturbances and autonomic regulation in military personnel.
    Read more: https://www.sciencedirect.com/science/article/pii/S1389945718303095

---

Appendix: Detailed HBOT Protocol for Sleep Apnea 🗂️

This appendix provides an excessively detailed breakdown of the Hyperbaric Oxygen Therapy (HBOT) protocol proposed for Sleep Apnea (SA) patients, including specific settings, patient selection criteria, treatment schedules, monitoring parameters, safety precautions, and long-term follow-up considerations.

A. Patient Selection Criteria

A.1 Inclusion Criteria

The HBOT protocol is designed for OSA and CSA patients who meet at least one of the following conditions:

• Moderate-to-Severe Obstructive Sleep Apnea (OSA) (AHI ≥ 15 events/hour) with:
  • Persistent hypoxemia (SpO₂ < 90%) despite CPAP/BiPAP therapy.
  • Elevated cardiovascular risk (hypertension, atrial fibrillation, or history of stroke).
  • Neurocognitive impairments (memory loss, brain fog, impaired executive function).
• CPAP-Intolerant or CPAP-Noncompliant Patients, including:
  • Those with claustrophobia or psychological intolerance to CPAP.
  • Persistent excessive daytime sleepiness (EDS) despite optimal CPAP settings.
• Central Sleep Apnea (CSA) or Complex Sleep Apnea Syndrome (CompSAS) with:
  • Post-stroke respiratory control dysfunction.
  • Brainstem hypoperfusion affecting central respiratory drive.
  • Post-traumatic brain injury (TBI)-related autonomic dysregulation.
• Obesity Hypoventilation Syndrome (OHS) Patients who exhibit:
  • Severe nocturnal desaturation (SpO₂ < 85%) despite BiPAP therapy.
  • Pulmonary hypertension secondary to chronic alveolar hypoventilation.
• Post-COVID patients with residual sleep disturbances and neuroinflammation, presenting:
  • Autonomic dysfunction affecting sleep regulation.
  • Cognitive impairment and persistent fatigue.

A.2 Exclusion Criteria

• Chronic obstructive pulmonary disease (COPD) with CO₂ retention, due to potential oxygen toxicity risks.
• Active malignancies, as HBOT may stimulate angiogenesis and tumor proliferation.
• History of untreated pneumothorax or barotrauma susceptibility, which could be exacerbated by HBOT pressure changes.
• Seizure disorders, due to HBOT’s potential to lower seizure threshold in some patients.
• Severe claustrophobia, unless treated with behavioral therapy or anxiolytics.

B. HBOT Protocol Settings and Parameters

B.1 Atmospheric Pressure and Oxygen Concentration

• Target Pressure: 1.5–2.0 ATA (atmospheres absolute).
• Oxygen Concentration: 100% oxygen via a tight-fitting mask or chamber hood.
• Rationale for Pressure Selection:
  • 1.5 ATA: Optimal for mild-to-moderate SA with hypoxia and autonomic dysfunction.
  • 2.0 ATA: Recommended for severe SA with persistent desaturation (SpO₂ < 85%).

B.2 Session Duration and Treatment Schedule

• Session Duration: 60–90 minutes per session.
• Frequency: 5 sessions per week (Monday–Friday).
• Total Sessions: 20–40 sessions, depending on patient response.
• Phase 1: Intensive Oxygenation Phase (Sessions 1–20)
  • Daily HBOT sessions to achieve maximal oxygen saturation improvements.
  • Pre- and post-session oximetry measurements to assess oxygen retention effects.
• Phase 2: Neuroplasticity Optimization (Sessions 21–40)
  • Additional 10–20 sessions for patients with severe neurocognitive impairment or persistent autonomic dysregulation.
• Phase 3: Maintenance Therapy (Optional)
  • 1 session per week for 3–6 months, depending on long-term patient response.
  • Recommended for patients with persistent hypoxia or high cardiovascular risk.

B.3 Oxygen Delivery Methods

Patients will receive 100% oxygen through one of three delivery methods:

1. Monoplace Hyperbaric Chamber:
   Entire chamber pressurized with 100% oxygen.
   Ensures consistent oxygen delivery without mask discomfort.
   Preferred for CPAP-intolerant patients.
2. Multiplace Hyperbaric Chamber with Hood or Mask:
   Pressurized chamber with oxygen masks/hoods for individual patients.
   Allows direct supervision by medical staff.
3. Hybrid Approach with CPAP Integration:
   Patients can combine HBOT with CPAP therapy, particularly for those:
   • Undergoing CPAP desensitization.
   • Requiring dual treatment for airway patency and oxygenation.

C. Monitoring and Safety Measures

C.1 Pre-Treatment Evaluation

Before starting HBOT, each patient undergoes:

• Polysomnography (PSG) Baseline Assessment:
  • Apnea-Hypopnea Index (AHI).
  • Oxygen Desaturation Index (ODI).
  • Sleep latency and efficiency metrics.
• Cardiovascular Evaluation:
  • 24-hour blood pressure monitoring to assess nocturnal hypertension.
  • Heart rate variability (HRV) testing for autonomic function assessment.
• Cognitive Function Testing:
  • Montreal Cognitive Assessment (MoCA) for baseline neurocognitive deficits.
  • P300 auditory evoked potentials to track cognitive improvements.

C.2 In-Session Monitoring

During each HBOT session, patients are monitored for:

• Oxygen saturation (SpO₂) and transcutaneous CO₂ levels to prevent hyperoxia-induced respiratory depression.
• Heart rate and HRV variability, with continuous ECG monitoring for patients at high cardiovascular risk.
• Middle ear pressure adjustments, using Valsalva maneuvers or tympanostomy tubes if necessary.

C.3 Post-Treatment Follow-Up Assessments

• Polysomnography (PSG) Re-Evaluation
  Post-HBOT sleep study after 20–40 sessions to measure AHI, ODI, and total sleep efficiency changes.
• Cognitive and Autonomic Function Testing
  Repeat MoCA, HRV analysis, and autonomic reflex tests after treatment completion.
• Long-Term Monitoring (3–6 months post-treatment)
  Biannual polysomnographic assessments for sustained AHI reduction.
  Home pulse oximetry testing for residual nocturnal desaturation.

D. Risk Mitigation Strategies

D.1 Managing Potential Side Effects

Potential Risk	Mitigation Strategy
Oxygen Toxicity (CNS Seizures)	Limit exposure to ≤2.0 ATA, avoid prolonged sessions, monitor CO₂ retention.
Barotrauma (Middle Ear, Pulmonary)	Use slow pressurization rates, teach Valsalva techniques.
Hyperoxic Myopia (Reversible)	Screen for pre-existing myopia, limit prolonged HBOT exposure.
Oxidative Stress Rebound	Post-treatment antioxidant supplementation (Vitamin C, NAC).

E. Proposed Research Design for HBOT in Sleep Apnea

A randomized controlled trial (RCT) is recommended to validate HBOT’s role in SA management.

E.1 Study Design

• Three arms:
  • HBOT (2.0 ATA, 60 min, 30 sessions) + Standard CPAP Therapy.
  • Sham HBOT (1.1 ATA, normoxic conditions) + Standard CPAP Therapy.
  • HBOT Monotherapy for CPAP-intolerant patients.

E.2 Primary and Secondary Outcomes

• Primary Outcomes:
  • Reduction in AHI and nocturnal hypoxia burden.
  • Improvements in sleep efficiency and cognitive function.
• Secondary Outcomes:
  • Changes in inflammatory biomarkers (CRP, TNF-α, IL-6).
  • Cardiovascular benefits (BP reduction, HRV stabilization).